Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for glucocorticoid-induced hyperglycemia during acute exacerbation of COPD
NL-OMON41812Phase 4Active, not recruiting
- Sponsor
- Slotervaartziekenhuis
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in corticosteroid-induced hyperglycemia (GIH) comparing Dapagliflozin with Placebo (2 arms). Primary endpoints: Effectiveness primary endpoint and Safety primary endpoint. Started Feb 2015; status: active, not recruiting.
02
Drugs
dapagliflozin
03
Conditions
corticosteroid-induced hyperglycemia (GIH)
Beyond the preview
Go deeper on NL-OMON41812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41812.